Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Nature Clinical Practice. Neurology
|
February 7, 2007
Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?
Hillel Panitch
Expert Opinion on Pharmacotherapy
|
June 4, 2011
Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability
Hillel Panitch, Angela Applebee
Biologics : Targets & Therapy
|
August 27, 2009
Early stage and long term treatment of multiple sclerosis with interferon-beta
Angela Applebee, Hillel Panitch
Journal of Neuroimmunology
|
November 30, 2010
Combination therapy in multiple sclerosis
Ron Milo, Hillel Panitch
Journal of the Neurological Sciences
|
April 17, 2007
Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
Ariel Miller, Hillel Panitch
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 9, 2004
Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization
Yang Mao-Draayer, Hillel Panitch
Neurology
|
November 24, 2004
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study
Hillel Panitch, Aaron Miller, Donald Paty, et al.
Neurology
|
October 9, 2002
Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange
Yang Mao-Draayer, Steven Braff, William Pendlebury, et al.
Biochemical and Biophysical Research Communications
|
July 22, 2009
The effect of interferon-beta on mouse neural progenitor cell survival and differentiation
Marek Hirsch, Julia Knight, Mari Tobita, et al.
Journal of Neuroimmunology
|
March 3, 2007
Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response
Jerome J Graber, David Ford, Min Zhan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Nature Clinical Practice. Neurology
|
February 7, 2007
Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?
Hillel Panitch
Expert Opinion on Pharmacotherapy
|
June 4, 2011
Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability
Hillel Panitch, Angela Applebee
Biologics : Targets & Therapy
|
August 27, 2009
Early stage and long term treatment of multiple sclerosis with interferon-beta
Angela Applebee, Hillel Panitch
Journal of Neuroimmunology
|
November 30, 2010
Combination therapy in multiple sclerosis
Ron Milo, Hillel Panitch
Journal of the Neurological Sciences
|
April 17, 2007
Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
Ariel Miller, Hillel Panitch
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 9, 2004
Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization
Yang Mao-Draayer, Hillel Panitch
Neurology
|
November 24, 2004
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study
Hillel Panitch, Aaron Miller, Donald Paty, et al.
Neurology
|
October 9, 2002
Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange
Yang Mao-Draayer, Steven Braff, William Pendlebury, et al.
Biochemical and Biophysical Research Communications
|
July 22, 2009
The effect of interferon-beta on mouse neural progenitor cell survival and differentiation
Marek Hirsch, Julia Knight, Mari Tobita, et al.
Journal of Neuroimmunology
|
March 3, 2007
Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response
Jerome J Graber, David Ford, Min Zhan, et al.
Page
of 2